RenovoRx (NASDAQ:RNXT) is Profiled in this Database

Updated At 08 Sep, 2021

Start Free 7 Day Trial Now
Partial description of this company
Solution for targeted delivery of fluids, including radiopaque material and therapeutic agents, to selected sites in the peripheral vascular system at high concentration to specific visceral organs - safely and without perfusion overlap to other organs; targets include pancreatic cancer

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of RenovoRx (NASDAQ:RNXT) plus 5035 other startups.

Start Free 7 Day Trial Now

Learn More About RenovoRx (NASDAQ:RNXT)

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

More

Our Clients